Search

Your search keyword '"G. Gasbarrini"' showing total 307 results
Start Over Author "G. Gasbarrini" Topic hepatology
307 results on '"G. Gasbarrini"'

2. P.09.10 CIRRHOTIC PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY PRESENT INCREASED CEREBRAL VASCULAR RESISTANCE, WHICH REMAINS UNCHANGED AFTER MEDICAL TREATMENT

Author

B. Funaro, Andrea Lupascu, M.E. Ainora, G. Gasbarrini, Brigida E. Annicchiarico, M. Siciliano, Paolo Tondi, Alessandro Gasbarrini, Maurizio Pompili, Laura Riccardi, F.R. Ponziani, Maria Assunta Zocco, M. Garcovich, and A. Quadarella

Subjects
medicine.medical_specialty, Hepatology, Medical treatment, business.industry, Internal medicine, Gastroenterology, medicine, medicine.disease, business, Cerebral vascular resistance, Hepatic encephalopathy
Published
2018

3. P.02.13: Can Gender Affect Dob Values Obtained by 13-C Urea Breath Test?

Author

C. Petruzziello, Valentina Tesori, Marcello Candelli, Alessandro Gasbarrini, Maurizio Gabrielli, G. Gasbarrini, Francesco Franceschi, Veronica Ojetti, and Cristina Graziani

Subjects
Hepatology, medicine.diagnostic_test, business.industry, Urea breath test, Anesthesia, Gastroenterology, Medicine, business, Affect (psychology)
Published
2017

4. P.09.30 NEW DIRECT-ACTING ANTIVIRAL (DAA) THERAPY IMPACTS LIVER STIFFNESS MEASUREMENTS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION

Author

B. Funaro, M.E. Ainora, M. Garcovich, Maria Assunta Zocco, G. Gasbarrini, Annalisa Tortora, M. Siciliano, F.R. Ponziani, G. Gibiino, Maurizio Pompili, Alessandro Gasbarrini, T. Lembo, and Laura Riccardi

Subjects
Hepatology, Chronic hepatitis, business.industry, Liver stiffness, Immunology, Gastroenterology, Medicine, In patient, business, Virus, Direct acting
Published
2018

5. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease

Author

Silvia Delgado-Aros, Michael Camilleri, G. Gasbarrini, Antonio Gasbarrini, S. Di Caro, Antonia R. Sepulveda, and Filippo Cremonini

Subjects
medicine.medical_specialty, Hepatology, biology, Exacerbation, business.industry, Gastroenterology, Case-control study, Odds ratio, Helicobacter pylori, medicine.disease, biology.organism_classification, humanities, digestive system diseases, Clinical trial, Gastro, Internal medicine, Meta-analysis, medicine, GERD, Pharmacology (medical), business
Abstract

Summary Background: The relationship between Helicobacter pylori infection and its treatment and gastro-oesophageal reflux disease (GERD) is controversial. Aims: To establish if H. pylori infection is associated with the presence of GERD and if anti-H. pylori treatment leads to de novo GERD or rebound/exacerbation of GERD. Methods: A search of MEDLINE and EMBASE databases was made. Pooled odds ratios (OR) were calculated for de novo GERD and rebound/exacerbated GERD after anti-H. pylori therapy in case-control studies and in therapeutic trials. Results: Fourteen case-control studies and 10 clinical trials were included. Among case-control studies, pooled OR for the association between H. pylori negative status and GERD was 1.34 [95% confidence interval (CI) 1.15–1.55]. Among therapeutic trials, pooled OR for the association anti-H. pylori therapy – GERD was 2.54 (95% CI 1.92–3.37). The OR for de novo GERD was 3.25 (95% CI 2.09–5.33), and for rebound/exacerbated GERD was 2.39 (95% CI 1.75–3.34). Associations were higher among Asian studies than among North American and European studies. Conclusions: This meta-analysis shows significant association between absence of H. pylori infection and GERD symptoms, and a positive association between anti-H. pylori therapy and occurrence of both de novo and rebound/exacerbated GERD. The significance of these associations appears to have been inflated by the effect of single trials and by geographical variations.

Published
2003

6. Helicobacter pylori is an aetiological factor for ischaemic heart disease: the case against

Author

Giovanni Cammarota, Alessandro Gasbarrini, V. Pasceri, and G. Gasbarrini

Subjects
Pathology, medicine.medical_specialty, Heart disease, Myocardial Ischemia, Congenital cytomegalovirus infection, Disease, Global Health, Helicobacter Infections, Coronary artery disease, Risk Factors, Internal medicine, Prevalence, medicine, Humans, Chlamydia, Helicobacter pylori, Hepatology, biology, business.industry, Incidence, Incidence (epidemiology), Gastroenterology, biology.organism_classification, medicine.disease, Clinical trial, business
Abstract

Helicobacter pylori is one of four organisms often investigated for ari association with ischaemic heart disease. The four, including Chlamydia pneumoniae, Cytomegalovirus and Herpes virus, cause low-grade, life-long infections that can produce a persistent inflammation, the kind that leads to heart disease. Several studies suggest an association, but others suggest none. Patients with poor access to medical care are more likely to become infected and also more likely to suffer from coronary artery disease. Although the literature data are provocative and interesting, the two things may not be related. Helicobacter pylori infection is quite prevalent among individuals without ischaemic heart disease and absent in many of those with ischaemic heart disease. Thus, more definite answers about whether there is any link between Helicobacter pylori and cardiovascular disease are needed. It would be essential to establish the specific mechanisms that possibly confer vulnerability or protection toward coronaropathy. But a definite answer could come from clinical trials designed to test whether antibiotics can prevent the disease. Until now, no randomised trial has suggested a positive effect of Helicobacter pylori eradication in reducing the incidence of cardiac events.

Published
2000

7. [Untitled]

Author

G. Gasbarrini, I Massari, Michele Serricchio, Roberto Flore, De Luca A, Dal Lago A, Angelo Santoliquido, Francesco Franceschi, Paolo Pola, Ojetti, P. Tondi, and Antonio Gasbarrini

Subjects
medicine.medical_specialty, biology, medicine.diagnostic_test, Physiology, business.industry, Vascular disease, Spirillaceae, Urea breath test, Gastroenterology, Vasospasm, Hepatology, Helicobacter pylori, biology.organism_classification, medicine.disease, Surgery, Pharmacotherapy, Internal medicine, medicine, Gastritis, medicine.symptom, business
Abstract

Raynaud's phenomenon is defined by anintermittent vasospasm of the arterioles of the distallimbs. Helicobacter pylori infection has been recentlyassociated with Raynaud's phenomenon. The aim of this study was to assess the effects of H. pylorieradication on Raynaud's attacks. Forty-six patientsaffected by primary Raynaud's phenomenon were evaluated.H. pylori infection was assessed by [13C]urea breath test. Eradication therapy was given toinfected patients for seven days. Discomfort and theduration and frequency of attacks of Raynaud'sphenomenon per week were assessed. Thirty-six subjectswere infected with H. pylori; the bacterium waseradicated in 83% of these after therapy. Attacks ofRaynaud's phenomenon completely disappeared in 17% ofthe patients with H. pylori eradication. Discomfort and the duration and frequency of attacks ofRaynaud's phenomenon were significantly reduced in 72%of the remaining patients. Conversely, attacks ofRaynaud's disease did not change significantly during the 12-week follow-up period either in the H.pylori-negative patients or in the infected subjects inwhom the bacterium was not eradicated by therapy. Thestudy shows that H. pylori eradication causes a significant decrease in clinical attacks ofRaynaud's disease. The reduction of vasoactivesubstances determined by the eradication of thebacterium may be the pathogenetic mechanism underlyingthe phenomenon.

Published
1998

8. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival

Author

TREVISANI, FRANCO, CANTARINI, MARIA CHIARA, MORSELLI LABATE, ANTONIO MARIA, DE NOTARIIS, STEFANIA, ZOLI, MARCO, BERNARDI, MAURO, CARACENI, PAOLO, NARDO, BRUNO, GOLFIERI, RITA, Rapaccini G., Farinati F., Del Poggio P., Di Nolfo M. A., Benvegnù L., Borzio F., P. Andreone, M. Biselli, M. Cantarini, C. Cursaro, M. Domenicali, GRAMENZI, ANNAGIULIA, S. Li Bassi, D. Magalotti, F. Mirici Cappa A. Zambruni, DI MARCO, MARIACRISTINA, E. Vavassori, L. Gilardoni, M. Mattiello, A. Alberti, A. Gatta, M. Gios, M. Covino, G. Gasbarrini, A. Baldan, D. Marino, A. Sergio, M. Molaro, M. Sala, GRAZI, GIAN LUCA, M. Ravaioli, C. Rossi, Italian Liver Cancer group, Trevisani F., Cantarini M.C., Morselli Labate A.M., De Notariis S., Rapaccini G., Farinati F., Del Poggio P., Di Nolfo M.A., Benvegnù L., Zoli M., Borzio F., Bernardi M., P. Andreone, M. Biselli, P. Caraceni, M. Cantarini, C. Cursaro, M. Domenicali, A. Gramenzi, S. Li Bassi, D. Magalotti, F. Mirici Cappa A. Zambruni, M. Di Marco, E. Vavassori, L. Gilardoni, M. Mattiello, A. Alberti, A. Gatta, M. Gio, M. Covino, G. Gasbarrini, A. Baldan, D. Marino, A. Sergio, M. Molaro, M. Sala, G.L. Grazi, B. Nardo, M. Ravaioli, C. Rossi, R. Golfieri, and Italian Liver Cancer (ITALICA) group

Subjects
Liver Cirrhosis, Male, PROGNOSIS, Cirrhosis, FEATURES, Gastroenterology, CHRONIC LIVER-DISEASE, INFECTION, CHRONIC LIVER-DISEASE, DIAGNOSIS, CHEMOEMBOLIZATION, EXPERIENCE, MANAGEMENT, PROGNOSIS, INFECTION, FEATURES, TRIALS, CHEMOEMBOLIZATION, CIRRHOSIS, Ultrasonography, Liver Neoplasms, Age Factors, humanities, Survival Rate, TRIALS, Liver, Hepatocellular carcinoma, SURVIVAL, Female, alpha-Fetoproteins, HEPATOCELLULAR CARCINOMA, ELDERLY, SURVEILLANCE, medicine.medical_specialty, Carcinoma, Hepatocellular, DIAGNOSIS, Internal medicine, MANAGEMENT, Carcinoma, medicine, Biomarkers, Tumor, Humans, Survival rate, Cancer staging, Aged, Retrospective Studies, Hepatology, business.industry, Retrospective cohort study, Patient survival, social sciences, medicine.disease, digestive system diseases, Multicenter study, EXPERIENCE, business
Abstract

Surveillance of cirrhotic individuals for early detection of HCC, based on ultrasonography (US) and alpha1-fetoprotein (AFP) determination, is a recommended practice currently applied also to elderly patients. However, several age-related factors may jeopardize the results of surveillance in these patients. Aim of the study was to evaluate the benefit of surveillance for HCC in elderly individuals.Multicenter retrospective study on 1,277 consecutive patients with HCC. The inclusion criteria were: underlying chronic liver disease, description of cancer stage, and modalities of its diagnosis. Among the 1,037 patients fulfilling these criteria, 363 agedor = 70 yr were considered.The tumor was detected during surveillance, based on US and AFP performed every 6-12 months, in 158 individuals (group 1), incidentally in 138 (group 2) and because of symptoms in 67 (group 3). Surveillance reduced the risk of dealing with an advanced cancer (odds ratio (95% Confidence Interval): 0.18 (0.09-0.37) vs group 3, and 0.29 (0.17-0.49) vs group 2). The frequency of effective treatments decreased from group 1 to group 3 (73%, 57%, and 31%, respectively). The main cause of death was HCC progression. The survival corrected for the lead time of group 1 (median: 24 months) was significantly better than the crude survival of group 3 (7 months; p= 0.003) and barely better than that of group 2 (21 months). The latter also showed a better prognosis with respect to group 3 (p= 0.018).Surveillance for HCC improves the survival of elderly cirrhotic patients by expanding the percentage of cancers amenable to effective treatments.

Published
2004

9. OC.04.3 PATIENT-TARGETED AND MULTIDISCIPLINARY MANAGEMENT IMPROVES SURVIVAL IN PATIENTS WITH HCC: THE HEPATOCATT EXPERIENCE

Author

T.A. Di Rienzo, Emanuele Rinninella, Maurizio Pompili, Alessandro Gasbarrini, Mariachiara Campanale, S.G. Hepatocatt, M. Montagna, Valentina Cesario, G.L. Rapaccini, Brigida E. Annicchiarico, G. Gasbarrini, A. Grieco, F. D'Aversa, and M. Siciliano

Subjects
medicine.medical_specialty, Hepatology, business.industry, Multidisciplinary approach, Gastroenterology, medicine, In patient, Intensive care medicine, business
Published
2014

10. P.15.4 EFFECT OF THE SUPPLEMENTATION OF A HIGH-DOSE AMOXICILLIN BASED TRIPLE THERAPY WITH FRUCTO OLIGOSACCHARIDES LACOTFERRIN AND BACILLUS COAGULANS IN PATIENTS UNDERGOING H. PYLORI ERADICATION

Author

Francesco Franceschi, Alessandro Gasbarrini, Giuseppe Zuccalà, G. D'Angelo, T.A. Di Rienzo, Annalisa Tortora, and G. Gasbarrini

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Gastroenterology, Amoxicillin, biology.organism_classification, Microbiology, Internal medicine, medicine, Bacillus coagulans, In patient, business, medicine.drug
Published
2014

11. P.01.7 AMPK ACTIVATION IN COLON CANCER CELLS INHIBITS THE MALIGNANT PHENOTYPE INDUCING DIFFERENTIATION: POTENTIAL USE OF METFORMIN IN THE TREATMENT OF COLORECTAL CANCER

Author

Valentina Tesori, Alessandro Gasbarrini, G. Gasbarrini, S. Chiatamone Ranieri, and Maria Ausiliatrice Puglisi

Subjects
Oncology, medicine.medical_specialty, Hepatology, Colorectal cancer, business.industry, Gastroenterology, AMPK, medicine.disease, Metformin, Internal medicine, medicine, business, Malignant phenotype, medicine.drug
Published
2014

12. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference

Author

A, Gasbarrini, G R, Corazza, G, Gasbarrini, M, Montalto, M, Di Stefano, G, Basilisco, A, Parodi, P, Usai-Satta, P U, Satta, P, Vernia, C, Anania, M, Astegiano, G, Barbara, L, Benini, P, Bonazzi, G, Capurso, M, Certo, A, Colecchia, L, Cuoco, A, Di Sario, D, Festi, C, Lauritano, E, Miceli, G, Nardone, F, Perri, P, Portincasa, R, Risicato, M, Sorge, A, Tursi, A.Gasbarrini, G.R.Corazza, G.Gasbarrini, M.Montalto, M.Di Stefano, G.Basilisca, A.Parodi, P.U.Satta, P.Vernia, C.Anania, M.Astegiano, G.Barbara, L.Benini, P.Bonazzi, G.Capurso, M.Certo, A.Colecchia, L.Cuoco, A.Di Sario, D.Festi, C.Lauritano, E.Miceli, G.Nardone, F.Perri, P.Portincasa, R.Risicato, M.Sorge, and A.Tursi.

Subjects
Adult, medicine.medical_specialty, Hydrogen analysis, Gastrointestinal Diseases, consensus conference, Settore MED/12 - GASTROENTEROLOGIA, Mouthwashes, Specimen Handling, Breath testing, Small intestinal bacterial overgrowth, medicine, Dietary Carbohydrates, Humans, Hyperventilation, gastroenterology diseases, Pharmacology (medical), Intensive care medicine, Child, Gastrointestinal Transit, breath tests, Exercise, Breath test, Evidence-Based Medicine, Hepatology, medicine.diagnostic_test, Methane biosynthesis, business.industry, Cathartics, Medical screening, digestive, oral, and skin physiology, Smoking, Gastroenterology, Consensus conference, food and beverages, Bacterial Infections, medicine.disease, Surgery, Diet, Gases, business, Hydrogen breath test, Methane, Hydrogen
Abstract

Breath tests represent a valid and non-invasive diagnostic tool in many gastroenterological conditions. The rationale of hydrogen-breath tests is based on the concept that part of the gas produced by colonic bacterial fermentation diffuses into the blood and is excreted by breath, where it can be quantified easily. There are many differences in the methodology, and the tests are increasingly popular.The Rome Consensus Conference was convened to offer recommendations for clinical practice about the indications and methods of H2-breath testing in gastrointestinal diseases.Experts were selected on the basis of a proven knowledge/expertise in H2-breath testing and divided into Working Groups (methodology; sugar malabsorption; small intestine bacterial overgrowth; oro-coecal transit time and other gas-related syndromes). They performed a systematic review of the literature, and then formulated statements on the basis of the scientific evidence, which were debated and voted by a multidisciplinary Jury. Recommendations were then modified on the basis of the decisions of the Jury by the members of the Expert Group.The final statements, graded according to the level of evidence and strength of recommendation, are presented in this document; they identify the indications for the use of H2-breath testing in the clinical practice and methods to be used for performing the tests.

Published
2009

13. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection

Author

R. Finizio, Veronica Ojetti, Giovanni Cammarota, Giuseppe Pignataro, Filippo Cremonini, Maria Assunta Zocco, G. Gasbarrini, Enrico Celestino Nista, Antonio Gasbarrini, Marcello Candelli, Maria Mercedes Santoro, and Immacolata A. Cazzato

Subjects
Adult, Male, medicine.medical_specialty, Settore MED/12 - GASTROENTEROLOGIA, Moxifloxacin, Gastroenterology, Tinidazole, law.invention, Esomeprazole, Helicobacter Infections, Randomized controlled trial, law, Clarithromycin, Internal medicine, medicine, Humans, Pharmacology (medical), Prospective Studies, Dyspepsia, Antibacterial agent, Aza Compounds, Hepatology, biology, Helicobacter pylori, business.industry, Amoxicillin, Middle Aged, bacterial infections and mycoses, biology.organism_classification, Surgery, Treatment Outcome, Quinolines, Patient Compliance, Drug Therapy, Combination, Female, business, medicine.drug, Fluoroquinolones
Abstract

SUMMARY Background: Standard anti-Helicobacter pylori therapy may not achieve a satisfactory eradication rate. Fluoroquinolones, such as moxifloxacin, are safe and promising agents for H. pylori eradication. Aim: To compare the efficacy of two 1-week moxifloxacin-based H. pylori eradication regimens with two standard treatments. Methods: Three hundred and twenty H. pylori-positive subjects were randomized into four groups to receive: moxifloxacin, amoxicillin, esomeprazole (Group MAE); moxifloxacin, tinidazole and esomeprazole (Group MTE); standard triple therapies with clarithromycin, amoxicillin and esomeprazole (Group CAE) or tinidazole (Group CTE) for 7 days. H. pylori status was re-assessed 6 weeks after the end of therapy by 13C urea breath test. Results: Three hundred and twenty patients completed the efficacy analysis per protocol; H. pylori eradication rate in group MTE was 90% (72 of 80) and 92% (72 of 78), in group MAE was 88% (70 of 80) and 89%, (70 of 79) in Group CAE was 73% (58 of 80) and 78% (58 of 74), and in Group CTE was 75% (60 of 80) and 79% (60 of 76), respectively, in intention-to-treat and in per protocol analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than that observed using standard triple schemes. The incidence of side effects was significantly lower in moxifloxacin groups than in control groups. Conclusions: Seven-day moxifloxacin-based triple therapies provide optimal eradication rates with a good compliance when compared with the standard triple therapy schemes.

Published
2005

14. P.11.15 IMPACT OF PORTAL VEIN THROMBOSIS ON HEPATOCELLULAR CARCINOMA TREATMENT OUTCOME. THE HEPATOCAT GROUP EXPERIENCE

Author

A. De Gaetano, Davide Roccarina, Mariachiara Campanale, F.R. Ponziani, Giuseppe Caracciolo, G. Gasbarrini, Felice Giuliante, A.W. Avolio, T.A. Di Rienzo, M. Garcovich, Gianluca Ianiro, F. Barbaro, Emanuele Rinninella, Brigida E. Annicchiarico, R. Zaccaria, G. Sarno, G.L. Rapaccini, Maurizio Pompili, Alessandro Gasbarrini, Maria Assunta Zocco, Valentina Cesario, Giovanni Gigante, Annalisa Tortora, A. Grieco, M. Siciliano, F. D'Aversa, Gennaro Nuzzo, Salvatore Agnes, and A. Milani

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Treatment outcome, Gastroenterology, medicine, medicine.disease, business, Portal vein thrombosis
Published
2013

15. P.11.18 GUT MICROBIOTA ALTERATION: THE LINK BETWEEN 'LEAKY GUT' AND SPONTANEOUS BACTERIAL PERITONITIS IN LIVER CIRRHOTIC PATIENTS?

Author

Clara Balsano, M.E. Ainora, Alessandro Gasbarrini, M. Garcovich, Emidio Scarpellini, G. Gasbarrini, Maurizio Gabrielli, Maria Assunta Zocco, Venanzio Valenza, Annalisa Tortora, and F.R. Ponziani

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Gastroenterology, Gut flora, medicine.disease, biology.organism_classification, Microbiology, Spontaneous bacterial peritonitis, Internal medicine, medicine, Gut permeability, business
Published
2013

16. OC.12.5 ROLE OF NITROGEN SPECIES IN COLON CANCER STEM CELLS

Author

Giovambattista Pani, Ezio Giorda, A. Cittadini, W. Lattanzi, Rita Carsetti, Fabrizio Michetti, Valentina Tesori, G. Gasbarrini, Maria Ausiliatrice Puglisi, and Alessandro Gasbarrini

Subjects
Hepatology, chemistry, business.industry, Colorectal cancer, Gastroenterology, Cancer research, Medicine, chemistry.chemical_element, Stem cell, business, medicine.disease, Nitrogen
Published
2013

17. P.06.16 EFFICACY OF AMYTRIPTILINE IN IMPROVING INTESTINAL PERMEABILITY AND QUALITY OF LIFE IN PATIENTS WITH IBS

Author

Annalisa Tortora, Alessandro Gasbarrini, Veronica Ojetti, Giuseppe Caracciolo, Giovanni Cammarota, Venanzio Valenza, Valentina Cesario, Gianluca Ianiro, G. Gasbarrini, Mariachiara Campanale, and Giovanni Gigante

Subjects
medicine.medical_specialty, Quality of life (healthcare), Intestinal permeability, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, In patient, business, medicine.disease
Published
2013

18. P.13.7 COMPARISON BETWEEN TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) AND TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION COMBINED WITH PERCUTANEOUS RADIOFREQUENCY ABLATION (TACE-RFA) FOR TREATMENT OF INTERMEDIATE HEPATOCELLULAR CARCINOMA (HCC)

Author

Lorenzo Bonomo, Maurizio Pompili, F.R. Ponziani, A. Grieco, Roberto Iezzi, Valentina Cesario, F. D'Aversa, A. De Gaetano, T.A. Di Rienzo, Maria Assunta Zocco, Brigida E. Annicchiarico, G. Gasbarrini, A. Guerra, M. Siciliano, G.L. Rapaccini, Salvatore Agnes, F. Barbaro, Emanuele Rinninella, M. La Torre, Felice Giuliante, Laura Riccardi, Gennaro Nuzzo, Mariachiara Campanale, Giovanni Gigante, and Alessandro Gasbarrini

Subjects
medicine.medical_specialty, Percutaneous, Hepatology, business.industry, Radiofrequency ablation, Gastroenterology, medicine.disease, law.invention, law, Hepatocellular carcinoma, medicine, Radiology, Transcatheter arterial chemoembolization, business
Published
2013

19. Enterocyte actin autoantibody detection: a new diagnostic tool in celiac disease diagnosis: results of a multicenter study

Author

P Strisciuglio, Lucia Cicotto, M P Musu, Mauro Congia, Mg Clemente, Gino Roberto Corazza, Tarcisio Not, Umberto Volta, G. Gasbarrini, S. De Virgiliis, Gabriella Sole, Giuseppe Maggiore, Carolina Ciacci, Riccardo Troncone, Alessio Fasano, Elena Neri, Clemente, Mg, Musu, Mp, Troncone, Riccardo, Volta, U, Congia, M, Ciacci, C, Neri, E, Not, T, Maggiore, G, Strisciuglio, Pietro, Corazza, Gr, Gasbarrini, G, Cicotto, L, Sole, G, Fasano, A, and DE VIRGILIIS, S.

Subjects
Biopsy, Fluorescent Antibody Technique, Disease, medicine.disease_cause, Coeliac disease, Autoimmunity, Immunopathology, Prospective Studies, Intestinal Mucosa, Fluorescent Antibody Technique, Indirect, Child, Cells, Cultured, Cultured, Gastroenterology, Middle Aged, medicine.anatomical_structure, Child, Preschool, Adult, Indirect, Adolescent, Enterocyte, Cells, Socio-culturale, Sensitivity and Specificity, Double-Blind Method, Predictive Value of Tests, medicine, Humans, Actins, Aged, Autoantibodies, Biomarkers, Celiac Disease, Enterocytes, Immunoglobulin A, Infant, Retrospective Studies, Transglutaminases, Preschool, Actin, Hepatology, business.industry, Autoantibody, nutritional and metabolic diseases, medicine.disease, digestive system diseases, Multicenter study, Immunology, business
Abstract

This study describes a new method to detect autoantibodies against actin filaments (AAA) as a serological marker of intestinal villous atrophy (IVA) in celiac disease (CD), and reports the results of an Italian double-blind multicenter study.IgA-AAA were analyzed by immunofluorescence using a newly developed method based on intestinal epithelial cells cultured in presence of colchicine. IgA-AAA were blindly evaluated prospectively in 223 antiendomysial antibody (AEA) and/or antitransglutaminase antibody (TGA) positive subjects and in 78 AEA and TGA negative subjects. IgA-AAA positive patients underwent an intestinal biopsy to confirm the diagnosis. Moreover, IgA-AAA were retrospectively investigated in 84 biopsy-proven CD patients and in 2,000 new consecutively collected serum samples from AEA and TGA negative nonbiopsied subjects.IgA-AAA were positive in 98.2% of the CD patients with flat mucosa, in 89% with subtotal villous atrophy, and in 30% with partial villous atrophy. IgA-AAA were present in none of the AEA and TGA negative nonbiopsied controls. In AEA and/or TGA positive CD patients IgA-AAA positivity significantly correlated with IVA (p0.000 in the prospective study, p = 0.005 in the retrospective study). In the prospective study, the values of sensitivity, specificity, the positive predictive value, the negative predictive value, and the efficiency of the IgA-AAA test to identify patients with IVA were, respectively, 83.9%, 95.1%, 97.8%, 69.2%, and 87.0%. Furthermore, a significant correlation (p0.0001) was found between the IgA-AAA serum titre and the degree of IVA (rs 0.56).The results of this multicenter study show that the new method for IgA-AAA detection could represent a practical diagnostic tool in AEA and/or TGA positive subjects, which would be especially useful when IVA shows a patchy distribution, when the histological picture is difficult to interpret, or when a biopsy could represent a life-threatening risk.

Published
2004

20. 151 REDUCED DOSE AND DURATION OF SORAFENIB TREATMENT ARE ASSOCIATED TO TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Author

Valentina Cesario, M. Siciliano, Giuseppe Caracciolo, Michele A. Basso, Giovanni Gigante, F.R. Ponziani, G. Gasbarrini, G. Sarno, Alessandro Gasbarrini, M. Garcovich, B.E. Annichiarico, Mariachiara Campanale, Emanuele Rinninella, F. D'Aversa, Carlo Barone, Maria Assunta Zocco, and T.A. Di Rienzo

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Tumor progression, Internal medicine, Hepatocellular carcinoma, Sorafenib treatment, Medicine, In patient, business, medicine.disease, Reduced dose
Published
2012

21. P.08.13 REDUCED DOSE AND DURATION OF SORAFENIB TREATMENT ARE ASSOCIATED TO TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Author

T.A. Di Rienzo, Brigida E. Annicchiarico, F. D'Aversa, Mariachiara Campanale, Maria Assunta Zocco, Emanuele Rinninella, Giovanni Gigante, Carlo Barone, Alessandro Gasbarrini, M. Garcovich, Giuseppe Caracciolo, Michele A. Basso, G. Gasbarrini, G. Sarno, F.R. Ponziani, M. Siciliano, and Valentina Cesario

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Sorafenib treatment, Reduced dose, medicine.disease, Tumor progression, Internal medicine, Hepatocellular carcinoma, medicine, In patient, business
Published
2012

23. F-23 Lack of response and tumor recurrence after multimodal repeated treatment for hepatocellular carcinoma similarly affect HCC patients survival. A HEPATOCAT group experience

Author

Giuseppe Caracciolo, Alessandro Gasbarrini, Maurizio Pompili, Maria Assunta Zocco, Valentina Cesario, A. Milani, T.A. DiRienzo, Salvatore Agnes, Felice Giuliante, Gennaro Nuzzo, G.L. Rapaccini, R. Zaccaria, G. Gasbarrini, A. De Gaetano, Annalisa Tortora, A. Grieco, V. Gigante, M. Siciliano, Emanuele Rinninella, F. D'Aversa, M. Garcovich, F.R. Ponziani, Brigida E. Annicchiarico, C. Campanale, and G. Sarno

Subjects
Oncology, medicine.medical_specialty, Repeated treatment, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Gastroenterology, medicine, business, Affect (psychology), medicine.disease, Tumor recurrence
Published
2012

24. T-21 Single-step balloon-occluded percutaneous radio-frequency thermal ablation (RFA) plus transcatheter arterial chemoembolization (TACE) for treatment of 'complex' unresectable hepatocellular carcinoma

Author

R. Iezzi, V. Cesario, M. Campanale, T.A. DiRienzo, G. Gigante, G. Caracciolo, E. Rinninella, F.R. Ponziani, M. La Torre, B.E. Annicchiarico, M. Siciliano, M. Pompili, A. Grieco, L. Miele, M. Santoro, G.L. Rapaccini, L. Riccardi, M.A. Zocco, A. Milani, A.M. De Gaetano, G. Gasbarrini, L. Bonomo, and A. Gasbarrini

Subjects
Hepatology, Gastroenterology
Published
2012

25. OC.08.3: IDENTIFICATION OF ENDOTHELIN-1 AND NR4A2 AS CD133-REGULATED GENES IN COLON CANCER CELLS

Author

Anna Chiara Piscaglia, Maria Ausiliatrice Puglisi, G. Gasbarrini, Nathalie Saulnier, A. Cittadini, Marta Barba, Alessandro Gasbarrini, E. Giorda, M.F. Errico, Rita Carsetti, Alessandro Sgambato, and Alma Boninsegna

Subjects
Hepatology, Colorectal cancer, business.industry, Gastroenterology, Cancer research, medicine, Cancer, Identification (biology), medicine.disease, business, Somatic evolution in cancer, Endothelin 1, Gene
Published
2011

26. P.1.303: HIGH DOSE AMOXICILLIN-BASED FIRST LINE REGIMEN IS EQUIVALENT TO SEQUENTIAL THERAPY IN THE ERADICATION OF H. PYLORI INFECTION

Author

N. Gentiloni Silveri, Annalisa Tortora, Annarita Carroccia, Giovanni Cammarota, Davide Marsiliani, F. Barbaro, G. Gasbarrini, R. Finizio, Valentina Cesario, Francesco Franceschi, Alessandro Gasbarrini, Mariachiara Campanale, Giovanni Gigante, G. Bombardieri, S. Calcinaro, and Diego Currò

Subjects
medicine.medical_specialty, Regimen, Hepatology, business.industry, First line, Internal medicine, Gastroenterology, medicine, Amoxicillin, H pylori infection, business, medicine.drug
Published
2011

27. OC.04.1: NICKEL FREE-DIET ENHANCES HELICOBACTER PYLORI ERADICATION RATE

Author

Eleonora Nucera, F. Purchiaroni, Veronica Ojetti, Domenico Schiavino, Flavio Bertucci, Valentina Cesario, Alessandro Gasbarrini, Annalisa Tortora, T.A. Di Rienzo, Mariachiara Campanale, T. De Pasquale, and G. Gasbarrini

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Internal medicine, Gastroenterology, medicine, Nickel free, Helicobacter pylori, biology.organism_classification, business
Published
2011

28. P.1.148: RIFAXIMIN TREATMENT FOR SMALL INTESTINAL BACTERIAL OVERGROWTH IN CHILDREN WITH IRRITABLE BOWEL SYNDROME

Author

Veronica Ojetti, Emidio Scarpellini, G. Gasbarrini, Maurizio Gabrielli, V. Giorgio, Annalisa Tortora, G. Vitale, Giovanni Gigante, S. Filoni, Carlo Fundarò, and Alessandro Gasbarrini

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Rifaximin, chemistry.chemical_compound, chemistry, Internal medicine, Small intestinal bacterial overgrowth, medicine, business, Irritable bowel syndrome
Published
2011

30. P.17.5 TREATMENT OF 'COMPLEX' UNRESECTABLE HEPATOCELLULAR CARCINOMA: PRELIMINARY RESULTS OF NEW THERAPEUTIC APPROACH (SINGLE-STEP BALLOON-OCCLUDED PERCUTANEOUS RADIO-FREQUENCY THERMAL ABLATION PLUS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE-RFA)

Author

Maurizio Pompili, S.G. Hepatocatt, Valentina Cesario, Lorenzo Bonomo, A. Grieco, A. De Gaetano, Emanuele Rinninella, Mariachiara Campanale, M. Siciliano, F. Barbaro, Maria Assunta Zocco, T.A. Di Rienzo, G. D'Angelo, A. Guerra, G. Gasbarrini, G.L. Rapaccini, Brigida E. Annicchiarico, Massimiliano Nestola, Alessandro Gasbarrini, M. La Torre, Alessandro Posa, and Roberto Iezzi

Subjects
medicine.medical_specialty, Percutaneous, Hepatology, business.industry, Gastroenterology, Thermal ablation, Single step, medicine.disease, Balloon, Therapeutic approach, Hepatocellular carcinoma, medicine, Radiology, business, Transcatheter arterial chemoembolization
Published
2014

31. P.01.1 EFFECT OF BACILLUS CLAUSII IN THE N-METHYLNITROSUREA INDUCED MODEL OF COLONRECTAL CANCER

Author

G. Gasbarrini, Francesco Franceschi, Franco Scaldaferri, B. Giupponi, Alessandro Rettino, G. De Marco, Alessandro Gasbarrini, Annalisa Tortora, Giuseppe Zuccalà, Viviana Gerardi, and Davide Roccarina

Subjects
Hepatology, biology, business.industry, Bacillus clausii, Gastroenterology, medicine, Cancer, medicine.disease, business, biology.organism_classification, Microbiology
Published
2014

32. OC.12.1 MORPHOLOGICAL FEATURES OF ENDOTHELIAL CELLS OF ENDOMETRIUM BEFORE AND AFTER INCUBATION WITH ANTI-TRANSGLUTAMINASE ANTIBODIES IN BOTH HEALTHY AND CELIAC WOMEN

Author

Gianluca Ianiro, Chiara Tersigni, N. Di Simone, M. Amici, M. De Spirito, Alessandro Gasbarrini, Giovanni Gigante, Franco Scaldaferri, S. De Martino, and G. Gasbarrini

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Gastroenterology, Endometrium, Endocrinology, medicine.anatomical_structure, Internal medicine, Anti-transglutaminase antibodies, medicine, biology.protein, business, Incubation
Published
2014

33. P.17.4 DOWNSTAGING THERAPY IN PATIENTS WITH INTERMEDIATE STAGE HCC (BCLC B) AS BRIDGE FOR TRANSPLANTATION: THE HEPATOCATT EXPERIENCE

Author

A. Grieco, F. D'Aversa, Brigida E. Annicchiarico, A.W. Avolio, Salvatore Agnes, Alessandro Gasbarrini, G. D'Angelo, G.L. Rapaccini, F. Barbaro, G. Gasbarrini, M. Siciliano, Roberto Iezzi, T.A. Di Rienzo, Mariachiara Campanale, S.G. Hepatocatt, A. De Gaetano, Maurizio Pompili, and Valentina Cesario

Subjects
Transplantation, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Medicine, In patient, business, Bridge (interpersonal), Intermediate stage, Surgery
Published
2014

34. C-Methacetin breath test in patients with nonalcoholic steatohepatitis after hypocaloric diet therapy

Author

B. Alfei, G. Gasbarrini, A. Armuzzi, Maria Assunta Zocco, Alessandra Forgione, P. DiRocco, A. Grieco, Alessandro Gasbarrini, Luca Miele, and Esmeralda Capristo

Subjects
Breath test, Nonalcoholic steatohepatitis, medicine.medical_specialty, Hepatology, medicine.diagnostic_test, business.industry, Settore MED/12 - GASTROENTEROLOGIA, Gastroenterology, N/A, Internal medicine, Medicine, In patient, business, Hypocaloric diet
Published
2001

36. Serum laminin levels in non alcoholic steatohepatitis

Author

Maurizio Pompili, Aldo V. Greco, A. Grieco, A. Caprodossi, Luca Miele, P. Di Rocco, G.L. Rapaccini, G. Gasbarrini, and Alessandro Bianco

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Settore MED/12 - GASTROENTEROLOGIA, steatohepatitis, Non alcoholic, medicine.disease, Endocrinology, Laminin, Internal medicine, medicine, biology.protein, Steatohepatitis, business
Published
2001

39. P.107 EFFECT OF BACILLUS CLAUSII ADMINISTRATION IN THE RECTAL MUCOSA OF MICE TREATED WITH INTRARECTAL INSTILLATION OF THE CARCINOGEN N-METHYLNITROSUREA

Author

N. Soulier, B. Giupponi, F. Mancini, G. De Marco, Anna Chiara Piscaglia, Giovanni Gigante, Francesco Franceschi, A. Puglisi, Davide Roccarina, F. Barbaro, Marco Marini, N. Gentiloni Silveri, G. Gasbarrini, Riccardo Ricci, and Alessandro Gasbarrini

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Bacillus clausii, Gastroenterology, biology.organism_classification, Surgery, Rectal mucosa, Internal medicine, medicine, business, Carcinogen
Published
2010

40. Epitope mapping of human antibody response against HCV/E2 glycoprotein by generation of monoclonal recombinant Fabs

Author

G. Gasbarrini, C. Di Campli, Roberto Burioni, Giovanni Fadda, A Desogus, Aldo Manzin, Francesca Bugli, Alessandro Gasbarrini, Burioni, Roberto, Bugli, F, Di Campli, C, Desogus, A, Manzin, A, Gasbarrini, A, Gasbarrini, G, and Fadda, G.

Subjects
Antibody response, Epitope mapping, Hepatology, Linear epitope, law, Mimotope, Monoclonal, Recombinant DNA, Biology, Virology, Epitope, law.invention
Published
2000

41. Assessment of liver mitochondrial beta-oxidation by sodium C-13-octanoate breath test

Author

A De Lorenzo, Filippo Cremonini, Alessandro Gasbarrini, Paolo Pola, Luca Miele, G. Gasbarrini, A. Armuzzi, Maria Assunta Zocco, and A. Grieco

Subjects
Breath test, Chromatography, Hepatology, medicine.diagnostic_test, N/A, Chemistry, Sodium, Settore MED/12 - GASTROENTEROLOGIA, medicine, chemistry.chemical_element, Beta oxidation
Published
2000

42. BIOCHEMICAL RESPONSE TO URSODEOXYCHOLIC ACID AND LONG-TERM PROGNOSIS IN PRIMARY BILIARY CIRRHOSIS

Author

Tony Andreani, N. Rabahi, Christophe Corpechot, Raoul Poupon, Olivier Chazouillères, Catherine Johanet, G. Gasbarrini, Francesco Luzza, Yves Chrétien, and Ludovico Abenavoli

Subjects
medicine.medical_specialty, Primary biliary cirrhosis, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, medicine.disease, business, Ursodeoxycholic acid, medicine.drug, Term (time)
Published
2009

43. PA.194 VALUE OF THE WATER-IMMERSION TECHNIQUE DURING UPPER ENDOSCOPY IN EVALUATING DUODENAL VILLOUS ATROPHY IN CELIAC CHILDREN

Author

Orazio Genovese, A. Pantanella, Giovanni Cammarota, Carlo Fundarò, V. Giorgio, Gianluca Ianiro, G. Gasbarrini, Alessia Cazzato, and Paola Cesaro

Subjects
medicine.medical_specialty, Hepatology, Duodenal villous atrophy, business.industry, Water immersion, Internal medicine, Upper endoscopy, Gastroenterology, Medicine, business, Value (mathematics)
Published
2008

44. PA.79 SMALL INTESTINAL BACTERIAL OVERGROWTH OF COLONIC-TYPE CARBOHIDRATES FERMENTATIVE BACTERIA IN CIRRHOTIC PATIENTS

Author

Ernesto Cristiano Lauritano, R. Finizio, Maria Grazia Spitilli, A. Dal Lago, Giuseppe Merra, Maurizio Gabrielli, Alessandro Gasbarrini, Giovanni Ghirlanda, Maria Mercedes Santoro, Emidio Scarpellini, G. Gasbarrini, and Venanzio Valenza

Subjects
Hepatology, biology, business.industry, Small intestinal bacterial overgrowth, Gastroenterology, Medicine, business, medicine.disease, biology.organism_classification, Bacteria, Microbiology
Published
2008

45. PA.92 A PROPOSAL MODEL FOR THE NON-INVASIVE ASSESSMENT OF HISTOLOGICAL INFLAMMATION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Author

V. Vero, Marco Biolato, A. Grieco, Luca Miele, Consuelo Cefalo, M.L. Gabrieli, G. Gasbarrini, Alessandra Forgione, S. Racco, Fabio Maria Vecchio, V. Vellone, and A. Caprodossi

Subjects
medicine.medical_specialty, Hepatology, business.industry, Non invasive, Fatty liver, Gastroenterology, Inflammation, Non alcoholic, Disease, medicine.disease, Internal medicine, Medicine, In patient, medicine.symptom, business
Published
2008

46. PA.53 SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) IN PATIENTS WITH DUODENOGASTRIC REFLUX (DGR) POST-CHOLECYSTECTOMY

Author

Alessandro Gasbarrini, Matteo Garcovich, E.C. Lauritano, A De Lorenzo, G. Vitale, Immacolata A. Cazzato, Giovanni Cammarota, G. Gasbarrini, and Davide Roccarina

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, medicine.disease, Internal medicine, Small intestinal bacterial overgrowth, Duodenogastric Reflux, Medicine, Cholecystectomy, In patient, business
Published
2008

48. PO.14 GASTROINTESTINAL AMYLOIDOSIS: A POSSIBLE CAUSE OF CHRONIC DIARRHEA

Author

Elena Verrecchia, M Giovinale, Valentina Curigliano, Raffaele Manna, G. Gasbarrini, A. Soriano, C. Cerquaglia, and C. Fonnesu

Subjects
medicine.medical_specialty, Hepatology, Chronic diarrhea, business.industry, Internal medicine, Gastroenterology, medicine, business, GASTROINTESTINAL AMYLOIDOSIS
Published
2008

49. PA.186 FABRY DISEASE AND SMALL INTESTINAL BACTERIAL OVERGROWTH: PREVALENCE AND CORRELATION WITH GASTROINTESTINAL SYMPTOMS

Author

Francesco Franceschi, Davide Roccarina, Daniela Antuzzi, Anna Zampetti, G. Gasbarrini, Valentina Cesario, G. Vitale, Giovanni Gigante, M.E. Ainora, N. Gentiloni Silveri, B. Giupponi, Alessandro Gasbarrini, Claudio Feliciani, Ernesto Cristiano Lauritano, and G. De Marco

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Small intestinal bacterial overgrowth, Gastroenterology, medicine, medicine.disease, business, Fabry disease
Published
2008

Catalog

Books, media, physical & digital resources
See catalog results